Development and preliminarily validation of the Complementary Medicine Disclosure Index

McIntyre, Erica; Foley, Hope; Diezel, Helene; Harnett, Joanna; Adams, Jon; Sibritt, David; Steel, Amie

doi:10.1016/j.pec.2020.01.008

Cited by 14 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, our results align with previous studies that have shown there is limited communication between patients and their physicians about the use of CAM in general [5]. Interestingly, an important aspect in patients' disclosure of self-medication is the physician's question about whether they use CAM [5,25]. In addition, reasons for non-disclosure included fear of physician disapproval and perceived lack of relevance to the physician, lack of time, belief in the safety of CAM, and belief that the physician lacks knowledge about CAM [25].…”

Section: Discussionsupporting

confidence: 90%

“…Interestingly, an important aspect in patients' disclosure of self-medication is the physician's question about whether they use CAM [5,25]. In addition, reasons for non-disclosure included fear of physician disapproval and perceived lack of relevance to the physician, lack of time, belief in the safety of CAM, and belief that the physician lacks knowledge about CAM [25]. Overall, it would be more desirable to have better communication between patient and physician regarding CAM, and this should be practiced.…”

Section: Discussionmentioning

confidence: 99%

“…Based on these findings, physicians should provide additional focus on the ▶ patients' own interventions and self-medication using CAM and on its effects. This could have a direct impact on treatment selection and success [23,25]. Also, better training options and literature developed from evidence-based research on the use of CAM should be provided to health care professionals.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

et al. 2021

View full text Add to dashboard Cite

Background and Aims Progressive legalization and increasing utilization of medical cannabis open up potential new applications, including for inflammatory bowel disease (IBD). This study aimed to collect current figures on the use of and experience with cannabis among IBD patients in Germany. Methods A 71-item questionnaire was mailed to a randomly selected representative sample of 1000 IBD patients. Results Questionnaires were returned by 417 patients (mean age 49.1 ± 17.0 years; 55.8 % women; 43.4 % ulcerative colitis and 54.7 % Crohn’s disease). Seventy-three respondents (17.5 %) stated past cannabis use for recreational purposes, while 12 users mentioned usage at the time the questionnaire was completed (2.9 %). Seventeen patients (4.1 %) indicated past use of cannabis, and 18 participants (4.3 %) reported current use of cannabis to treat IBD. Perceived benefits of cannabis use by its users included reduced abdominal pain, improved sleep quality, and relief of unease and worry. They reported lower quality of life and higher levels of anxiety or depression than non-users. Of notice, 52.9 % of cannabis users obtained their cannabis from the black market. A total of 76.5 % of former and 50 % of current users did not report their cannabis use to the physician. Conclusion This survey reveals the largest data set on cannabis use among IBD patients in Germany, with the potential for further research. Cannabis is mainly procured from the black market, with unknown quality.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Finally, the disclosure indices limited responses regarding reasons to predetermined lists without opportunity for participants to provide open-text responses. Nevertheless, the indices were developed through rigorous examination of existing, expansive literature and the measures were subject to validation analyses [ 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…Health communication items included initial questions that asked about rates of disclosure to each type of health professional consulted (Disclosed ALL, Disclosed SOME, Did NOT disclose). Participants were then presented with two novel measures, which were subsequently subjected to validation analyses after data collection: the Complementary Medicine Disclosure Index (CMDI; disclosure/non-disclosure of CM to conventional medical providers) [15], and the Conventional Medicine Disclosure Index (CONMED-DI; disclosure/non-disclosure of conventional medicine to CM practitioners) [16]. These indices each consisted of two lists of items measuring the reasons for: a) disclosure; and b) non-disclosure of the relevant medicine type, and were assessed with a five-point Likert scale ranging from Strongly disagree (1) to Strongly agree (5).…”

Section: Instrumentmentioning

confidence: 99%

Disclosure of conventional and complementary medicine use to medical doctors and complementary medicine practitioners: A survey of rates and reasons amongst those with chronic conditions

et al. 2021

Self Cite

View full text Add to dashboard Cite

Chronic conditions are prolonged and complex, leading patients to seek multiple forms of care alongside conventional treatment, including complementary medicine (CM). These multiple forms of care are often used concomitantly, requiring patient-provider communication about treatments used in order to manage potential risks. In response, this study describes rates and reasons for disclosure/non-disclosure of conventional medicine use to CM practitioners, and CM use to medical doctors, by individuals with chronic conditions. A survey was conducted online in July and August 2017 amongst the Australian adult population. Participants with chronic conditions were asked about their disclosure-related communication with CM practitioners (massage therapist, chiropractor, acupuncturist, naturopath) and medical doctors. Patients consulting different professions reported varying disclosure rates and reasons. Full disclosure (disclosed ALL) to medical doctors was higher (62.7%-79.5%) than full disclosure to CM practitioners (41.2%-56.9%). The most strongly reported reason for disclosing to both MDs and CM practitioners was I wanted them to fully understand my health status, while for non-disclosure it was They did not ask me about my CM/medicine use. Reasons regarding concerns or expectations around the consultation or patient-provider relationship were also influential. The findings suggest that patient disclosure of treatment use in clinical consultation for chronic conditions may be improved through patient education about its importance, direct provider inquiry, and supportive patient-provider partnerships. Provision of optimal patient care for those with chronic conditions requires greater attention to patient-provider communication surrounding patients’ wider care and treatment use.

show abstract

The Use of Medications and Dietary Supplements by Masters Athletes — a Review

Harnett

Climstein

Walsh³

et al. 2022

Curr Nutr Rep

Self Cite

View full text Add to dashboard Cite

Purpose of Review Masters athletes (MA) are generally considered healthier than their sedentary peers. However, the prevalence of chronic conditions in any population increases with age. Treatments involve pharmacological and non-pharmacological interventions. A substantial proportion of the general population also use dietary supplements (DS). This raises questions about the potential for drug-nutrient interactions which may lead to adverse effects. We sought to determine the potential for drug-nutrient interactions MA may be exposed to by examining the prevalence of chronic conditions treated with medications and their DS use. Recent Findings Common conditions in MA include hypertension, hyperlipidemia, asthma, osteoarthritis, depression and anxiety. Treatments may involve prescribed medications. Few recent studies were identified on DS use; however, indications are for around 60% prevalence of supplement usage. Summary The higher prevalence of DS use by MA may result in drug-nutrient interactions that impact the effectiveness and safety of prescribed medications for chronic conditions.

show abstract

Development and preliminarily validation of the Complementary Medicine Disclosure Index

Cited by 14 publications

References 24 publications

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

Disclosure of conventional and complementary medicine use to medical doctors and complementary medicine practitioners: A survey of rates and reasons amongst those with chronic conditions

The Use of Medications and Dietary Supplements by Masters Athletes — a Review

Contact Info

Product

Resources

About